Kornimate/medical-research-clean huggingface dataset:
effect of palm olein intake on lipid profile and appetite regulation

Conditions: Lipidaemia

Summary: aims: to investigate whether acute ingestions of palm oil will have an effect on appetite regulation design: a randomized, single blind, cross over design including 4 single study visits separated by a week. visit 1 is an acclimatization visit followed by visit 2,3, and 4 where different types of fat will be given. population: 12 healthy males and females aged between 18 and 60 years with body mass index (bmi) between 18.5- 29.9kg/m2 and normal fasting plasma glucose and no evidence of insulin resistance will be recruited. no-pre existing morbidity including cardiac, hepatic or renal disease, history of diabetes, hypertension or hyperlipidaemia. treatment: acclimatization visit: at visit 1, all participants will be given a milkshake like drink containing fat, protein and carbohydrate. a cannula will be inserted for the duration of the study day but no blood will be taken. studies show than during the first visit stress response can affect the metabolic response to the study drink resulting in inaccurate results. study visit 2,3,4: following the acclimatization visit, participants will attend 3 more study visits separated by a week to test the metabolic response to the following fats: palm olein, interesterified palm olein and soybean oil in random order. participants will be asked to complete a visual analogue scale questionnaire about their appetite at each time point. fasting and postprandial plasma glucose, insulin, appetite hormones and lipids will be measured.


Eligibility criteria:
inclusion criteria: * healthy and overweight male and female volunteers of all ethnicities (body mass index (bmi) of 18.5-29.9 kg/m2) * age between 18-60 years (inclusive) exclusion criteria: * abnormal liver function test (elevated alanine aminotransferase and aspartate transaminase)/ abnormal kidney function test (elevated plasma creatinine) * history of type 2 diabetes mellitus, cancer, stomach ulcers, drug abuse or alcoholism, gastrointestinal disorders like crohn's disease * smokers * on lipid/blood pressure- lowering medication/supplements * blood pressure\>140/90 mm hg * fasting total cholesterol \> 6.2 mmol/l * fasting triacylglyceride \> 2.0 mmol/l * subject must not be allergic to intervention * pregnancy and breastfeeding (pregnancy test will be undertaken at the screening visit) * subjects taking nutritional supplements or on any weight-loss programs * subjects who gained or lost ≥ 3kg weight in the past three months * subjects with history of hypo- and hyperthyroidism * subjects who are anaemic and those who donated blood within three months of the study
the effects of scapular taping techniques on grip strength and hand function

Conditions: Grip Strength; Hand Function

Summary: this study aims to investigate the effects of different types of taping applied to the scapular region on grip strength and hand function.

disorders in the alignment of the scapula can lead to mechanical disorders in the proximal. this can lead to a decrease in proximal stability and a negative effect on force production in the distal. kinesio tape can stimulate mechanoreceptors through the skin with applied tension, create positional awareness, improve fascia alignment and reduce edema. it is also used to lift soft tissues in areas with pain and inflammation or to limit and increase movement. rigid taping is performed using non-elastic material and is preferred to increase stabilization and prevent injuries . there are also studies showing that rigid tape increases sensorimotor and proprioceptive senses ). in a study it was shown that kinesio taping applied to the scapular region improved upper extremity function. in a studyi, it was found that taping improved function in those with lumbar radiculopathy and that elastic taping was more effective than rigid taping. although there are studies comparing kinesio taping and rigid taping on shoulder joint range of motion and muscle strength, there is no study examining the effects of different tapings applied to the scapular region on grip strength and hand function. in addition, the positive effects of shoulder stabilization exercises on hand skills and grip strength have been shown in the literature. studies examining taping and hand functions have generally focused on the forearm and finger areas. the relationship between interventions in the scapular region and grip strength and function has not been sufficiently investigated in the literature, and filling this gap is important for functional rehabilitation. previous studies have indicated that taping is effective in injuries affecting the scapular region and upper extremity. this study will examine the effects of different types of taping applied to the scapular region on grip strength and hand function.

Eligibility criteria:
inclusion criteria: * individuals aged between 18 and 25, * with undamaged skin tissue in the area where taping will be applied, * who are willing to participate in the study. exclusion criteria: * individuals with a pathology, disease, or disability affecting upper extremity function, * who have experienced trauma/surgery affecting motor and sensory function in the upper extremity and neck region within the last 6 months, * who have normal joint motion limitations in the neck, shoulder, elbow, hand, and wrist joints, * who have received corticosteroid treatment in the shoulder region within the last 3 months, * who have received physiotherapy within the last 3 months.

Keywords: grip strength hand function taping scapular taping
ropivacaine use in interscalene block; what is the minimal effective analgesic concentration (meac 90)

Conditions: Postoperative Pain

Summary: this study aim to calculate the minimal effective ropivacaine concentration required achieve successful analgesic interscalene block in 90% of patients (meac90)

* before induction of general anesthesia, all patients will receive interscalene block using 15ml of ropivacaine which concentration will be based on the response of the previous patient. * based on biased-coin design up-down sequential method: if patient has pain free recovery, a successful block, the next patient will be randomized to receive either the same ropivacaine concentration or a concentration 0.01% w/v less. however, if he has an unsuccessful block, the next patient will receive a concentration 0.01% w/v higher. * patients with pain free recovery will be considered to have positive response. * patients' responses will be analyzed to calculate the meac90.

Eligibility criteria:
inclusion criteria: * patients, who are scheduled for shoulder arthroscopy exclusion criteria: * - \<18 y, * asa physical class greater \>iii * bmi \>40 has any contraindication for medications or techniques used in the study
a phase i, open-label, multi-center study to assess the safety, tolerability and pharmacokinetics of azd6244 (arry-142886)

Conditions: Breast Cancer; Breast Neoplasms; Colon Cancer; Colonic Cancer; Colon Neoplasms; Lung Cancer; Melanoma; Kidney Cancer

Summary: this study is being conducted to determine if a combination of azd6244 given orally twice a day with standard doses of selected chemotherapies will be safe and tolerable for cancer patients with advanced solid tumors. the highest tolerated dose of azd6244 in combination with selected chemotherapies will be evaluated. the study will also investigate how azd6244 in combination with standard chemotherapies are absorbed, distributed and excreted by the body as well as the length of time that the drugs remain in the body. initial and periodic assessments will establish patient response to the combination therapies


Eligibility criteria:
inclusion criteria: * patients will have measurable and/or non-measurable disease, lacking curative options for whom the selected chemotherapy agents represent the standard of care * who performance status 0-1 * patients must be able to swallow azd6244 capsules exclusion criteria: * prior treatment with a mek inhibitor * participation in a clinical study during the last 30 days or have not recovered from side effects of an investigational study drug * brain metastases or spinal cord compression unless treated and stable (for at least 1 month) off steroids

Keywords: arry-142886 azd6244 cancer colon cancer breast cancer lung cancer melanoma kidney cancer
effect of sofosbuvir-daclatasuvir on angiogenesis

Conditions: HCV Coinfection

Summary: the study aimed at study of the effect of daclatasvir plus sofosbuvir on angiogenesis in egyptian patients with chronic hcv infection

the study primary aim was at evaluation of the effect of daclatasvir plus sofosbuvir on angiogenesis in egyptian patients with chronic hcv infection

Eligibility criteria:
inclusion criteria: * chronic hcv patients exclusion criteria: * hcc. * hiv or hbv. * malignancy. * pregnancy.
status of chronic liver disease in hepatitis c virus (hcv) patients coinfected with human immunodeficiency virus (hiv) in andalusia

Conditions: Chronic Hepatitis C; Human Immunodeficiency Virus (HIV)

Summary: this study evaluates the current situation and follow-up of chronic hepatitis c virus (hcv) infection in patients co-infected with human immunodeficiency virus (hiv) in andalusia.

in subjects co-infected with hiv, treatment of chronic hcv infection is particularly complex and requires considerable resources, including a very high cost is likely to increase with new antivirals. a precise knowledge of the situation in each hospital would facilitate adequate provision of personal and material resources needed to adequately address this disease in each center and in the community as a whole. because all or the vast majority of patients coinfected hiv / hcv are staffed by specialists who are part of hepavir group and / or sociedad andaluza de enfermedades infecciosas (saei), they are ideal for carrying out this study.

Eligibility criteria:
inclusion criteria: * patients over 18 with hiv infection and active chronic hepatitis or svr after treatment. exclusion criteria: * none
geriatric thoracic surgery ambulation challenge

Conditions: Thoracic Diseases; Surgery; Therapy, Exercise

Summary: this study is examining collecting data on steps walked (ambulation) per day by thoracic surgery patients over the age of 65 years-old before surgery. the name(s) of the study device involved in this study is: * fitbit inspire

this research study is a feasibility study, which is the first-time investigators are examining the use of a fitbit by thoracic surgery patients over the age of 65 years-old before surgery. the study is looking to see if patients can wear a wrist step-tracker and keep a log of their daily step counts for one week. the study is looking to see if people are willing to keep track of their daily steps, so in the future participants may be provided with step-goals to achieve and their steps prior to surgery can be accurately measured. this research study involves using a fitbit tracker to record daily steps over the course of 1 week prior to scheduled surgery. participants will be given a step tracker in clinic and instructed on its use. during the 1 week period, participants will be called by a study team to check on progress. after a week, participants will be asked to return the step-tracker and their log either at a scheduled pre-surgery clinic visit or in the pre-operative area which ever comes first. it is expected that about 30 people will take part in this research study.

Eligibility criteria:
inclusion criteria: * patients aged ≥ 65 years * who are preparing to undergo thoracic surgery at brigham and women's hospital (bwh) exclusion criteria: * patients who are completely non-ambulatory (i.e. wheelchair-bound-patients) \* * those who lack capacity to consent due to cognitive disease. * patient for which surgery is felt to be more urgent and therefore performed earlier then our required timeframe for intervention. * patients with cardiac disease or angina for which formal cardiac testing is required for clearance. * our exclusion criteria do not include patients with gait disturbances or those who require assistance devices for ambulation.

Keywords: thoracic diseases lung resection perioperative activity pedometer tracker
tramadol to reduce opioid withdrawal symptoms

Conditions: Opioid-Related Disorders

Summary: individuals with opioid addiction often experience serious withdrawal symptoms that may make relapse unavoidable. tramadol, a medication that is currently used to treat pain caused by chronic conditions such as cancer or joint pain, may also be effective at reducing opioid withdrawal symptoms. this study will evaluate the effectiveness of tramadol at reducing withdrawal symptoms in individuals addicted to opioid drugs.

opioid withdrawal symptoms are a major contributing factor for why opioid treatment programs often fail. individuals with severe opioid withdrawal symptoms may experience shaking, muscle and bone pain, nausea, depression, anxiety, and drug craving. tramadol is a medication that is currently used to treat moderate to severe pain in individuals with cancer, joint pain, or pain resulting from surgery. because of its pharmacological profile, tramadol may also be useful in treating opioid withdrawal. further research is needed to confirm the benefits of tramadol for opioid addicts. the purpose of this study is to evaluate the effectiveness of tramadol at reducing opioid withdrawal symptoms in opioid-dependent individuals. this 6-week inpatient study will enroll opioid-dependent individuals. participants will be required to reside at the research clinic for the entire study. all participants will receive morphine maintenance treatment on a daily basis. twice a week participants will take part in experimental challenge sessions in which they will be randomly assigned to receive varying doses of tramadol, naloxone, morphine, or placebo. these sessions will assess the ability of tramadol to suppress opioid withdrawal symptoms. participants will complete performance tasks to measure psychomotor and cognitive functioning. heart rate and blood pressure will be monitored throughout the experimental sessions. a specialized camera will also be used to assess pupillary response of the eyes. questionnaires and self-reports will be completed to assess medication effects and withdrawal symptoms. following the end of the study, all participants will be offered outpatient drug abuse treatment.

Eligibility criteria:
inclusion criteria: * meets dsm-iv diagnostic criteria for opioid dependence * is in good physical health * qualifies for treatment with opioid agonist therapy (e.g., methadone) * if female, must have a negative pregnancy test prior to study entry exclusion criteria: * evidence of significant medical illness (e.g., insulin dependent diabetes mellitus) * evidence of significant psychiatric illness (e.g., schizophrenia) * currently seeking treatment for substance abuse * pregnant or breastfeeding

Keywords: opiate addiction opiate dependence
a study of zasocitinib in adults with psoriatic arthritis who have or have not been treated with biologic medicines

Conditions: Psoriatic Arthritis

Summary: psoriatic arthritis (psa) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (pso). the main aim of the study is to know how well zasocitinib (tak-279) works in participants with active psa based on their previous experience with specific treatments. the participants will be treated with either zasocitinib, or placebo. participants will be in the study for up to 60 weeks.


Eligibility criteria:
inclusion criteria: age: 1. the participant is aged 18 years or older at the time of signing the informed consent form (icf). disease characteristics: 2. the participant has had signs and symptoms consistent with psa for at least 3 months. 3. the participant meets the classification criteria for psoriatic arthritis (caspar criteria). 4. the participant has active arthritis as shown by a minimum of \>=3 tender joints in tjc68 and \>=3 swollen joints in sjc66 at the screening and baseline (day 1) visits. 5. the participant has at least 1 active lesion of plaque pso \>=2 cm in diameter, or any nail or nail bed changes characteristic of pso. medications for psa: 6. the participant has had at least one of the following: 1. inadequate response to a nonsteroidal anti-inflammatory drug (nsaid), or 2. inadequate response to a conventional synthetic disease-modifying antirheumatic drug (csdmard), or 3. biological disease-modifying antirheumatic drug (dmard)-inadequate response (bio-ir): inadequate response to up to 2 biologic dmards. exclusion criteria: psa and pso: 1. the participant has other disease(s) that might confound the evaluations of benefit of zasocitinib therapy, including but not limited to rheumatoid arthritis, axial spondyloarthritis, systemic lupus erythematosus, lyme disease, gout, or fibromyalgia. 2. the participant has a concomitant comorbid skin condition that, in the opinion of the investigator, would interfere with the study assessments, such as evidence of non-plaque pso (erythrodermic, pustular, predominately guttate pso, inverse, or drug-induced pso).

Keywords: drug therapy latitude research program latitude psa latitude psa-3002
functional rehabilitation of older patients with schizophrenia

Conditions: Psychotic Disorders; Schizoaffective Disorder; Schizophrenia

Summary: the primary purpose of this project is to evaluate the efficacy of a group therapy intervention, cognitive behavioral social skills training (cbsst), that teaches social functioning skills and cognitive-behavioral compensatory aids to older patients with schizophrenia. cbsst, therefore, targets the multidimensional deficits that lead to disability in aging veterans with severe mental illness.

this is a randomized-controlled clinical trial comparing 2 treatment conditions: goal focused supportive care (sc); and cbsst. subjects (n=100) will be recruited, treated for 9 months and followed longitudinally for 9 months after treatment. a multidimensional evaluation of treatment outcome, including social functioning (primary outcome), neuropsychological functioning, cognitive insight, psychotic symptoms, and health services utilization, will be conducted at baseline, end of treatment (9-month follow-up), and 9 months post-treatment. 100 patients with schizophrenia or schizoaffective disorder will participate on a voluntary basis and will be paid $50.00 per assessment visit. subjects will not be paid or given any incentive for treatment. the following inclusion/exclusion criteria will be used: (i) voluntary informed consent for participation (given by the patient or conservator); (ii) age 45 or older; (iii) dsm-iv-diagnosis (apa, 1994) of schizophrenia or schizoaffective disorder at any stage of illness; (iv) no prior exposure to sst or cbt in the past 5 years; (v) level of care required at baseline does not interfere with outpatient group therapy participation (e.g., partial or inpatient hospitalization for psychiatric, or physical illness). we anticipate that we will be able to provide an empirically validated intervention that can be used by clinicians on multidisciplinary rehabilitation teams to reduce disability in aging patients with schizophrenia. the products from this research will be written research reports and a therapy manual and patient workbook to guide rehabilitation that can be disseminated (e.g., via the internet) to relevant clinicians.

Eligibility criteria:
inclusion criteria: * 45 years of age and older * dsm-iv diagnosis of schizophrenia or schizoaffective disorder * fluent in speaking, reading, and writing english * physically and psychiatrically stable enough to undergo various assessments in this study exclusion criteria: has not received cognitive behavioral therapy (cbt) or social skills training (sst) or dialectical behavioral therapy (dbt) in the past 5 years

Keywords: behavioral cognitive functioning older cbt rehabilitation schizophrenia skills social training
effect of a glucagon like peptide 1 (glp1) booster in healthy humans

Conditions: Blood Sugar; High; Overweight and Obesity; Fat Burn; Obesity; Heart Health Markers

Summary: background glp1 booster (gb) was designed to stimulate the endogenous production of glp1, which in turn releases insulin, controls blood glucose level, suppresses appetite and thus helps people lose weight. purpose the purpose of this study is to assess several clinical endpoints and questionnaires in healthy volunteers taking the new gb formula. scope the scope of this protocol covers the non-clinical portion as well as the assessment of several clinical endpoints and questionnaires. in brief, the non-clinical design will be an open-label study involving volunteers taking gb everyday for 12 weeks. data analysis will involve measuring the clinical endpoints across the group at different timepoints.


Eligibility criteria:
inclusion criteria: * volunteers must be over the age of 18. * volunteers cannot be smokers. * volunteers cannot be currently taking a dietary supplement or prescription for weight loss. * exercising volunteers must maintain their regimen consistently throughout the course of the 12-week study. * caffeine drinking volunteers must maintain their caffeine intake consistently throughout the course of the 12-week study. * volunteers need to be overweight but not obese, as defined by having a bmi between 25.0 and 29.9 exclusion criteria: * female volunteers who are pregnant or planning to become pregnant within the next three months. * volunteers who are taking any stimulant medications (e.g. adderall, adzenys, dexedrine, ritalin, methylphenidate, etc).
mel vs bucy+vp-16 conditioning regimen for mm undergoing auto-hsct

Conditions: Autologous Hematopoietic Stem Cell Transplantation; Conditioning; Multiple Myeloma

Summary: the purpose of this study is to evaluate the safety and efficacy of melphalan and bucy+vp-16 myeloablative conditioning regimens in multiple myeloma undergoing autologous hematopoietic stem cell transplantation.


Eligibility criteria:
inclusion criteria: * multiple myeloma patients * achieving at least vgpr after chemotherapy, then mobilizing and collecting of peripheral blood stem cells exclusion criteria: * any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure) * patients with any conditions not suitable for the trial (investigators' decision
epidemiological study to evaluate the prevalence of epidermal growth factor receptor (egfr) mutation status in patients with newly diagnosed locally advanced or metastatic non small cell lung cancer (nsclc)

Conditions: Non Small Cell Lung Cancer

Summary: to estimate the prevalence of egfr mutation in a representative sample of patients with newly diagnosed stage iiib/iv nsclc in spain (predominantly caucasian ethnicity).


Eligibility criteria:
inclusion criteria: * signed written informed consent * histologically confirmed locally advanced or metastatic nsclc (stage iiib/iv) exclusion criteria: * mixed histology of small cell and non-small cell lung cancer

Keywords: egfr mutation, non-small cell lung carcinoma, spain evaluate the prevalence of egfr mutation status in patients with newly diagnosed locally advanced or metastatic nsclc